These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34365871)

  • 1. A patent review of aldosterone synthase inhibitors (2014-present).
    Wu J; Ding X; Tan X
    Expert Opin Ther Pat; 2022 Jan; 32(1):13-28. PubMed ID: 34365871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selectivity of BI 689648, a Novel, Highly Selective Aldosterone Synthase Inhibitor: Comparison with FAD286 and LCI699 in Nonhuman Primates.
    Weldon SM; Cerny MA; Gueneva-Boucheva K; Cogan D; Guo X; Moss N; Parmentier JH; Richman JR; Reinhart GA; Brown NF
    J Pharmacol Exp Ther; 2016 Oct; 359(1):142-50. PubMed ID: 27481775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldosterone synthase inhibition in humans.
    Azizi M; Amar L; Menard J
    Nephrol Dial Transplant; 2013 Jan; 28(1):36-43. PubMed ID: 23045428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of Aldosterone Synthase.
    Weldon SM; Brown NF
    Vitam Horm; 2019; 109():211-239. PubMed ID: 30678857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension.
    Karns AD; Bral JM; Hartman D; Peppard T; Schumacher C
    J Clin Hypertens (Greenwich); 2013 Mar; 15(3):186-92. PubMed ID: 23458591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension.
    Awosika A; Cho Y; Bose U; Omole AE; Adabanya U
    Expert Opin Investig Drugs; 2023; 32(11):985-995. PubMed ID: 37883217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of N-[5-(6-Chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, a Cortisol-Sparing CYP11B2 Inhibitor that Lowers Aldosterone in Human Subjects.
    Papillon JP; Lou C; Singh AK; Adams CM; Ksander GM; Beil ME; Chen W; Leung-Chu J; Fu F; Gan L; Hu CW; Jeng AY; LaSala D; Liang G; Rigel DF; Russell KS; Vest JA; Watson C
    J Med Chem; 2015 Dec; 58(23):9382-94. PubMed ID: 26540564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baxdrostat: A Novel Aldosterone Synthase Inhibitor for Treatment Resistant Hypertension.
    Dogra S; Shah S; Gitzel L; Pusukur B; Sood A; Vyas AV; Gupta R
    Curr Probl Cardiol; 2023 Nov; 48(11):101918. PubMed ID: 37399857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldosterone synthase inhibitors for cardiovascular diseases: A comprehensive review of preclinical, clinical and in silico data.
    Lenzini L; Zanotti G; Bonchio M; Rossi GP
    Pharmacol Res; 2021 Jan; 163():105332. PubMed ID: 33271294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldosterone and aldosterone synthase inhibitors in cardiorenal disease.
    Verma S; Pandey A; Pandey AK; Butler J; Lee JS; Teoh H; Mazer CD; Kosiborod MN; Cosentino F; Anker SD; Connelly KA; Bhatt DL
    Am J Physiol Heart Circ Physiol; 2024 Mar; 326(3):H670-H688. PubMed ID: 38133623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldosterone synthase inhibitors in cardiovascular and renal diseases.
    Namsolleck P; Unger T
    Nephrol Dial Transplant; 2014 Feb; 29 Suppl 1():i62-i68. PubMed ID: 24493871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological treatment of aldosterone excess.
    Deinum J; Riksen NP; Lenders JW
    Pharmacol Ther; 2015 Oct; 154():120-33. PubMed ID: 26213109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel aldosterone synthase inhibitor ameliorates mortality in pressure-overload mice with heart failure.
    Furuzono S; Meguro M; Miyauchi S; Inoue S; Homma T; Yamada K; Tagawa YI; Nara F; Nagayama T
    Eur J Pharmacol; 2017 Jan; 795():58-65. PubMed ID: 27915044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 3-Pyridyl Isoindolin-1-one Derivatives as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors.
    Liu Y; Wu J; Zhou M; Chen W; Li D; Wang Z; Hornsperger B; Aebi JD; Märki HP; Kuhn B; Wang L; Kuglstatter A; Benz J; Müller S; Hochstrasser R; Ottaviani G; Xin J; Kirchner S; Mohr S; Verry P; Riboulet W; Shen HC; Mayweg AV; Amrein K; Tan X
    J Med Chem; 2020 Jul; 63(13):6876-6897. PubMed ID: 32530624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress towards clinically useful aldosterone synthase inhibitors.
    Cerny MA
    Curr Top Med Chem; 2013; 13(12):1385-401. PubMed ID: 23688131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of aldosterone synthase: Does this offer advantages compared with the blockade of mineralocorticoid receptors?
    Ando H
    Hypertens Res; 2023 Apr; 46(4):1056-1057. PubMed ID: 36653520
    [No Abstract]   [Full Text] [Related]  

  • 17. Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects.
    Ménard J; Rigel DF; Watson C; Jeng AY; Fu F; Beil M; Liu J; Chen W; Hu CW; Leung-Chu J; LaSala D; Liang G; Rebello S; Zhang Y; Dole WP
    J Transl Med; 2014 Dec; 12():340. PubMed ID: 25491597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Future drug discovery in renin-angiotensin-aldosterone system intervention.
    Tamargo M; Tamargo J
    Expert Opin Drug Discov; 2017 Aug; 12(8):827-848. PubMed ID: 28541811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mineralocorticoid receptor modulators: a patent review (2007 - 2012).
    Collin M; Niemann F; Jaisser F
    Expert Opin Ther Pat; 2014 Feb; 24(2):177-83. PubMed ID: 24215301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aldosterone Synthase Inhibitors and Mineralocorticoid Receptor Antagonists: Competitors or Collaborators?
    Pitt B; Williams GH
    Circulation; 2024 Feb; 149(6):414-416. PubMed ID: 38315762
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.